HEAD & NECK CANCERS

The patients with HNSCC had already been treated with immune checkpoint inhibitors and platinum-based chemotherapy.

"These findings support carboplatin-based IC-CCRT as a promising alternative treatment option for LA-NPC," Jian Guan, MD.

The AKT inhibitor ipatasertib resulted in 41% overall response rate when combined with pembrolizumab in head and neck squamous cell carcinoma.

Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors.

INBRX-106 may act as a costimulatory agent and enhance pembrolizumab outcomes in head and neck squamous cell carcinoma.

The FDA has agreed on the design of two phase 3 trials of the antibody-drug conjugate CRB-701 in HNSCC and cervical cancer.

Dr Mehra discussed HPV-positive oropharyngeal cancer, focusing on balancing high cure rates while minimizing toxicity through careful patient selection.

Proton therapy showed an advantage in early toxicity mitigation vs radiotherapy in patients with oropharyngeal squamous cell carcinoma.

Positive efficacy signals in progression-free survival (PFS) and objective response rate (ORR) did not translate into an overall survival (OS) benefit for first-line lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Three-year follow-up data from the phase 3 RATIONALE-309 trial show that tislelizumab plus chemotherapy provides durable progression-free survival and a clinically meaningful overall survival advantage over placebo in recurrent or metastatic nasopharyngeal carcinoma.

Clinical validation results show changes in methylated circulating tumor DNA (ctDNA) measured prior to treatment initiation and before cycle 3 of therapy were strongly associated with objective response and clinical benefit.

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer.

New research uncovers how genetic ancestry influences head and neck cancer biology, paving the way for personalized treatment strategies and improved patient outcomes.

A new clinical trial evaluates survival outcomes for recurrent head and neck cancer, comparing surgery with neoadjuvant chemotherapy and immunotherapy.

FDA fast-tracks BNT113, an mRNA immunotherapy, for treating HPV16+ head and neck cancer, enhancing immune responses alongside pembrolizumab.

Experts explore evolving treatment strategies for head and neck squamous cell carcinoma, emphasizing biomarker analysis and the importance of evidence-based guidelines.

A phase 2 trial reveals elraglusib shows potential benefits in select patients with recurrent salivary gland carcinomas despite missing primary response goals.

Whole-genome sequencing uncovers critical genomic insights in salivary gland cancer, paving the way for targeted therapies and improved patient outcomes.

FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies.

Enfortumab vedotin and pembrolizumab show promising first-line efficacy in treating recurrent metastatic head and neck cancer, with significant response rates.

Iza-bren shows significant improvement in response rates for recurrent nasopharyngeal carcinoma compared to chemotherapy, offering new hope for patients.

Xevinapant fails to enhance event-free survival (EFS) in head and neck cancer patients, revealing safety concerns and detrimental effects in treatment outcomes.

The FDA designates ficerafusp alfa as a breakthrough therapy for treating HPV-negative head and neck cancer, enhancing patient outcomes and options.